Brief: Jazz Pharmaceuticals Announce Positive Efficacy From Ziihera Phase 3 Trial
06/01/2026 19:17
Jan 6 (Reuters) - Jazz Pharmaceuticals PLC JAZZ.O: ZIIHERA® (ZANIDATAMAB-HRII) COMBINATIONS ACHIEVE UNPRECEDENTED RESULTS IN FIRST-LINE HER2+ LOCALLY ADVANCED OR METASTATIC GEA INCLUDING MORE THAN TWO YEARS MEDIAN OVERALL SURVIVAL BENEFIT JAZZ PHARMACEUTICALS PLC: ADDITIONAL PLANNED OS INTERIM ANALYSIS FOR ZIIHERA PLUS CHEMOTHERAPY IS CURRENTLY EXPECTED IN MID-2026 Source text: ID:nPnbkHfw4a Further company coverage: JAZZ.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jazz Pharmaceuticals
See all newsBrief: Jazz Pharmaceuticals Enters Amendment No. 4 To Credit Agreement On Sept 23, 2026
U.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Jazz Pharma dips after upsized $1.1 bln convertible offering
Brief: Jazz Pharmaceuticals Announces Private Offering Of $1.0 Billion Of Exchangeable Senior Notes Due 2032